$52.3 million of operating cash flow is the oddest number in Haemonetics’ latest report. It was roughly three times the year-earlier figure, even though net income declined.
The business itself grew at a measured pace in the three months ended June 27. Revenue rose 5.6%, and operating income increased 6.7%, but net income fell 3.0%. Gross margin stayed essentially flat, so the main split is not sales versus costs. It is cash generation versus profit below the operating line.
The cash surge came with a much smaller working-capital drag than a year earlier. Haemonetics said the prior period included $55.5 million of working-capital outflows, compared with $20.0 million in the latest period, which management linked to digital transformation costs.
"Cash flows from operations for fiscal 2027 period included net income of $33.0 million, adjusted for non-cash depreciation and amortization of $27.1 million and share-based compensation expense of $9.3 million, partially offset by cash outflows for working capital of $20.0 million driven by digital transformation costs."
Haemonetics, Form 10-Q, filed Aug. 6, 2026
In plain English, the cash conversion ratio moved from 0.51x to 1.59x. That is a substantial change in how much cash the reported earnings produced, though the balance sheet ended with $223.4 million of cash versus $292.9 million a year earlier. Haemonetics does not say why cash declined year over year.
The income statement had its own complication. Haemonetics said interest expense rose after it borrowed against its revolving credit facility, partly offset by gains tied to its prior Vivasure investment.
"The increase was primarily due to increase interest expense resulting from the borrowing of the revolving credit facility, partially offset by additional gains recognized on the previously held equity interest in Vivasure Medical Limited (“Vivasure”)."
Haemonetics, Form 10-Q, filed Aug. 6, 2026
That puts the 3.0% net-income decline below an operating line that improved. Operating margin edged up to 16.9% from 16.8%, while the company’s annual results for the year ended March 28 showed revenue down 2.0% and operating margin at 11.7%. The latest three-month period is therefore stronger than the immediately preceding annual backdrop, but its cash improvement also reflects a smaller working-capital outflow.
The sales increase was not uniform in description, though management pointed to higher market expansion in Vascular Closure, volume and share gains in Hemostasis Management, and volume growth in Plasma. Those are operating explanations for the revenue growth; they do not explain the cash balance or the net-income decline.
Shares closed at $83.60 on Aug. 5, down 2.1% that day. At the latest annual figures, the stock carried a 40.7x P/E, placing more attention on how much of the earnings improvement becomes repeatable operating cash rather than merely how fast sales grow.
The specific comparison in Haemonetics’ next 10-Q is operating cash flow against the $52.3 million produced in these three months, alongside the working-capital outflow that helped produce it.
Source: Haemonetics’ Form 10-Q for the three months ended June 27, 2026; operating cash flow was $52.3 million.